Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allah Ditta

Showing results (131-140 of 133) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 133 results.
BMJ Open Gastroenterology|October 7, 2025
Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn's disease in the UK: a multicentre retrospective cohort studyYaa Danso, Chandni Radia, Alex Elford, et al.
Journal of Crohn'S & Colitis|August 20, 2025
Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-Centre UK studyChandni Radia, Yaa Danso, Susan Ritchie, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Pageof 14

Showing results (131-140 of 133) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 133 results.
BMJ Open Gastroenterology|October 7, 2025
Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn's disease in the UK: a multicentre retrospective cohort studyYaa Danso, Chandni Radia, Alex Elford, et al.
Journal of Crohn'S & Colitis|August 20, 2025
Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-Centre UK studyChandni Radia, Yaa Danso, Susan Ritchie, et al.
Alimentary Pharmacology & Therapeutics|August 30, 2022
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring studyNeil Chanchlani, Simeng Lin, Marcus K Auth, et al.
Pageof 14